

and adopt, as well, and we can move forward in such a positive direction for people that you heard about today from my colleagues.

Lives that are on the line can be saved by innovation. The quicker we get that innovation to the market, the more we can reduce costs and save lives.

Mr. Speaker, I call on my colleagues to support passage of this very important lifesaving legislation, and I yield back the balance of my time.

Ms. ESHOO. Mr. Speaker, I rise today in support of H.R. 2430, the FDA Reauthorization Act of 2017 to reauthorize four important user fee programs: the Prescription Drug User Fee Act, the Medical Device User Fee Act, the Generic Drug User Fee Act, and the Biosimilar User Fee Act. These critically important laws have improved patient access to important therapies and expedited the FDA's approval times while upholding the most rigorous standards for patient safety.

The Prescription Drug User Fee Act (PDUFA) was enacted in 1992 when drug review times were lagging and FDA simply couldn't keep up with the flood of new drug applications. Through user fees paid by applicants, PDUFA gave FDA the resources it needed to hire and support more staff. The program has been successful in reducing review-time backlogs and expediting safe and effective therapies to patients.

My legislation created the Medical Device User Fee Act (MDUFA), which was enacted in 2002 and has resulted in significant changes to the medical device industry and within the medical device center at the FDA. Through this user fee program, the device center has improved its efficiency and reduced the time it takes to bring effective medical devices to market. This legislation builds on the progress made in previous user fee agreements and will produce important developments for the medical device industry.

The Generic Drug User Fee Agreement (GDUFA) was enacted in 2012 and takes important steps to bring lower-priced drugs to the market more quickly for the American people. Finally, the Biosimilar User Fee Agreement (BsUFA), which was first enacted in 2012 through legislation I authored, is critical to supporting the nascent biosimilar industry and will lead to meaningful progress, breakthroughs and cures for the American people.

Previous user fee reauthorizations have included significant gains for pediatric populations. Before the Better Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA), which I authored, the vast majority of drugs (more than 80 percent) used in children were used off-label, without data for their safety and efficacy. Today, that number has been reduced to 50 percent because of my legislation. Both programs were permanently reauthorized in 2012, and while this agreement includes important changes to BPCA and PREA, there remains a need for more meaningful improvements. This legislation lays important groundwork and provides the foundation for future progress.

Finally, I urge my colleagues in the Senate to take up this legislation swiftly. It's imperative that both houses of Congress pass this legislation and send it to the President in a timely manner for him to sign into law in order to provide essential resources to the FDA so they can continue to do their critical work.

Ms. MATSUI. Mr. Speaker, I rise today in support of H.R. 2430, the FDA user fee reauthorization bill that I worked on with my colleagues on the Energy & Commerce Committee.

Without Congress' swift action to reauthorize this bill, the FDA would not be able to conduct its critical work ensuring that our nation's drugs and devices are safe and effective.

Patients and families across the country battling diseases like Alzheimer's, cancer, multiple sclerosis (MS), and diabetes, rely on innovation to provide new life-saving and life-enhancing treatments and hopefully one day, cures. Without the FDA, we would not be able to ensure that those treatments and cures work and that they're safe.

To quote Dr. Jeff Allen of the Friends of Cancer Research, "for the people who currently depend on safe and effective medicines . . . for those who are holding strong for breakthroughs to come . . . and for every future patient . . . there isn't time to waste."

I urge my colleagues to support the passage of this bill.

Mrs. MIMI WALTERS of California. Mr. Speaker, I am pleased that the House is considering H.R. 2430, the FDA Reauthorization Act of 2017. I note that H.R. 2430 would provide the U.S. Food and Drug Administration (FDA) with new statutory authority to require the sponsor of an orphan-designated drug, which has certain similarities to an already approved drug, to demonstrate "clinical superiority" compared to the already approved drug as a condition of receiving seven years of market exclusivity.

This authority will limit the number of drugs that are automatically entitled to seven years of exclusivity, while maintaining incentives for the development of innovative treatments for rare diseases.

I also note that the bill would improve transparency of the FDA's execution of the Orphan Drug Act. Specifically, the bill directs the FDA to notify a sponsor in writing of any clinical superiority rationale on which the FDA relied in designating the sponsor's drug as an orphan drug. Further, it would require the FDA to publish its clinical superiority findings summaries for all drugs granted exclusivity based on a demonstration of clinical superiority.

I urge my colleagues to support the FDA Reauthorization Act of 2017.

The SPEAKER pro tempore (Mr. MURPHY of Pennsylvania). The question is on the motion offered by the gentleman from Oregon (Mr. WALDEN) that the House suspend the rules and pass the bill, H.R. 2430, as amended.

The question was taken; and (two-thirds being in the affirmative) the rules were suspended and the bill, as amended, was passed.

A motion to reconsider was laid on the table.

ANNOUNCEMENT BY THE SPEAKER PRO TEMPORE

The SPEAKER pro tempore. Pursuant to clause 8 of rule XX, proceedings will resume on questions previously postponed.

Votes will be taken in the following order:

Ordering the previous question on House Resolution 431;

Adopting House Resolution 431, if ordered; and

Suspending the rules and passing H.R. 1492.

The first electronic vote will be conducted as a 15-minute vote. Remaining electronic votes will be conducted as 5-minute votes.

PROVIDING FOR CONSIDERATION OF H.R. 2810, NATIONAL DEFENSE AUTHORIZATION ACT FOR FISCAL YEAR 2018, AND PROVIDING FOR CONSIDERATION OF H.R. 23, GAINING RESPONSIBILITY ON WATER ACT OF 2017

The SPEAKER pro tempore. The unfinished business is the vote on ordering the previous question on the resolution (H. Res. 431) providing for consideration of the bill (H.R. 2810) to authorize appropriations for fiscal year 2018 for military activities of the Department of Defense and for military construction, to prescribe military personnel strengths for such fiscal year, and for other purposes, and providing for consideration of the bill (H.R. 23) to provide drought relief in the State of California, and for other purposes, on which the yeas and nays were ordered.

The Clerk read the title of the resolution.

The SPEAKER pro tempore. The question is on ordering the previous question.

The vote was taken by electronic device, and there were—yeas 234, nays 183, not voting 16, as follows:

[Roll No. 347]

YEAS—234

Abraham	Cramer	Harper
Aderholt	Crawford	Harris
Allen	Culberson	Hartzler
Amash	Curbelo (FL)	Hensarling
Amodei	Davidson	Herrera Beutler
Arrington	Davis, Rodney	Hice, Jody B.
Babin	Denham	Higgins (LA)
Bacon	Dent	Hill
Banks (IN)	DeSantis	Holding
Barletta	DesJarlais	Hollingsworth
Barton	Diaz-Balart	Hudson
Bergman	Donovan	Huizenga
Biggs	Duffy	Hultgren
Bilirakis	Duncan (SC)	Hunter
Bishop (MI)	Duncan (TN)	Hurd
Bishop (UT)	Dunn	Issa
Black	Emmer	Jenkins (KS)
Blackburn	Estes (KS)	Jenkins (WV)
Blum	Farenthold	Johnson (LA)
Bost	Faso	Johnson (OH)
Brady (TX)	Ferguson	Jones
Brat	Fitzpatrick	Jordan
Bridenstine	Fleischmann	Joyce (OH)
Brooks (AL)	Flores	Katko
Brooks (IN)	Fortenberry	Kelly (MS)
Buchanan	Fox	Kelly (PA)
Buck	Franks (AZ)	King (IA)
Budd	Frelinghuysen	King (NY)
Burgess	Gaetz	Kinzinger
Byrne	Gallagher	Knight
Calvert	Garrett	Kustoff (TN)
Carter (GA)	Gianforte	Labrador
Carter (TX)	Gibbs	LaHood
Chabot	Gohmert	LaMalfa
Cheney	Goodlatte	Lamborn
Coffman	Gosar	Lance
Cole	Gowdy	Latta
Collins (GA)	Granger	Lewis (MN)
Collins (NY)	Graves (GA)	LoBiondo
Comer	Graves (LA)	Long
Comstock	Graves (MO)	Loudermilk
Conaway	Griffith	Love
Cook	Grothman	Lucas
Costello (PA)	Handel	Luetkemeyer

MacArthur Posey Smucker
 Marchant Ratcliffe Stefanik
 Marino Reed Stewart
 Marshall Reichert Stivers
 Massie Renacci Taylor
 Mast Rice (SC) Tenney
 McCarthy Roby Thompson (PA)
 McCaul Roe (TN) Thornberry
 McClintock Rogers (AL) Tiberi
 McHenry Rogers (KY) Tipton
 McKinley Rohrabacher Trott
 McMorris Rokita Turner
 Rodgers Rooney, Francis Upton
 McSally Rooney, Thomas Valadao
 Meadows J. Wagner
 Meehan Ros-Lehtinen Walberg
 Messer Roskam Walden
 Mitchell Ross Walker
 Moolenaar Rothfus Walorski
 Mooney (WV) Rouzer Walters, Mimi
 Mullin Royce (CA) Weber (TX)
 Murphy (PA) Russell Webster (FL)
 Newhouse Rutherford Wenstrup
 Noem Sanford Westerman
 Norman Schweikert Williams
 Nunes Scott, Austin Wittman
 Olson Sensenbrenner Womack
 Palazzo Sessions Woodall
 Palmer Shimkus Yoder
 Paulsen Shuster Yoho
 Pearce Simpson Young (AK)
 Perry Smith (MO) Young (IA)
 Pittenger Smith (NE) Zeldin
 Poe (TX) Smith (NJ)
 Poliquin Smith (TX)

NAYS—183

Adams Frankel (FL) Moore
 Aguilar Fudge Moulton
 Barragan Gabbard Murphy (FL)
 Bass Gallego Nadler
 Beatty Garamendi Neal
 Bera Gomez Nolan
 Beyer Gonzalez (TX) Norcross
 Bishop (GA) Gottheimer O'Halleran
 Blumenauer Green, Al O'Rourke
 Blunt Rochester Green, Gene Pallone
 Bonamici Grijalva Panetta
 Boyle, Brendan Gutiérrez Pascarell
 F. Hanabusa Payne
 Brady (PA) Hastings Perlmutter
 Brown (MD) Heck Peters
 Brownley (CA) Higgins (NY) Peterson
 Bustos Himes Pingree
 Butterfield Hoyer Pocan
 Capuano Huffman Polis
 Carbajal Jackson Lee Price (NC)
 Cárdenas Jayapal Quigley
 Carson (IN) Jeffries Raskin
 Cartwright Johnson (GA) Rice (NY)
 Castor (FL) Johnson, E. B. Richmond
 Castro (TX) Kaptur Rosen
 Chu, Judy Keating Roybal-Allard
 Cicilline Kelly (IL) Ruiz
 Clark (MA) Kennedy Ruppertsberger
 Clarke (NY) Kihuen Rush
 Clay Kilmer Ryan (OH)
 Cleaver Kind Sánchez
 Clyburn Kind Sarbanes
 Cohen Krishnamoorthi Schakowsky
 Connolly Kuster (NH) Schneider
 Conyers Langevin Schrader
 Cooper Larsen (WA) Scott (VA)
 Correa Larson (CT) Scott, David
 Courtney Lawrence Serrano
 Crist Lawson (FL) Sewell (AL)
 Cuellar Lee Sherman
 Davis (CA) Levin Sinema
 Davis, Danny Lewis (GA) Slaughter
 DeFazio Lipinski Smith (WA)
 DeGette Loeb sack Soto
 Delaney Lofgren Speier
 DeLauro Lowenthal Suozzi
 DelBene Lowey Swalwell (CA)
 Demings Lujan Grisham, Takano
 DeSaulnier M. Thompson (CA)
 Deutch Luján, Ben Ray Thompson (MS)
 Dingell Lynch Titus
 Doggett Maloney, Carolyn B. Tonko
 Doyle, Michael F. Maloney, Sean Tsongas
 Ellison Matsui Vargas
 Engel McCollum Veasey
 Eshoo McEachin Vela
 Espallat McGovern Velázquez
 Esty (CT) Mc Nerney Visclosky
 Evans Meeks Walz
 Foster Meng Wasserman

SchultzWaters, Maxine
 Watson Coleman Welch
 Wilson (FL) Yarmuth
 NOT VOTING—16
 Johnson, Sam Schiff
 Khanna Shea-Porter
 Lieu, Ted Sires
 Napolitano Torres
 Pelosi
 Scalise

ANNOUNCEMENT BY THE SPEAKER PRO TEMPORE

The SPEAKER pro tempore (during the vote). There are 2 minutes remaining.

□ 1444

Messrs. LOEBSACK and DAVID SCOTT of Georgia changed their vote from “yea” to “nay.”

So the previous question was ordered. The result of the vote was announced as above recorded.

Stated against:

Mr. SCHIFF. Mr. Speaker, I was unavoidably detained. Had I been present, I would have voted “nay” on rollcall No. 347.

The SPEAKER pro tempore. The question is on the resolution.

The question was taken; and the Speaker pro tempore announced that the ayes appeared to have it.

RECORDED VOTE

Mr. HASTINGS. Mr. Speaker, I demand a recorded vote.

A recorded vote was ordered.

The SPEAKER pro tempore. This will be a 5-minute vote.

The vote was taken by electronic device, and there were—ayes 232, noes 187, not voting 14, as follows:

[Roll No. 348]

AYES—232

Abraham Culberson Higgins (LA)
 Aderholt Curbelo (FL) Hill
 Allen Davidson Holding
 Amash Davis, Rodney Hollingsworth
 Amodei Denham Hudson
 Arrington Dent Huizenga
 Babin DeSantis Hultgren
 Bacon DesJarlais Hunter
 Banks (IN) Diaz-Balart Hurd
 Barton Donovan Issa
 Bergman Duffy Jenkins (KS)
 Biggs Duncan (SC) Jenkins (WV)
 Bilirakis Duncan (TN) Johnson (LA)
 Bishop (MI) Dunn Johnson (OH)
 Bishop (UT) Emmer Jones
 Black Estes (KS) Jordan
 Blackburn Farenthold Joyce (OH)
 Blum Faso Katko
 Bost Ferguson Kelly (MS)
 Brady (TX) Fitzpatrick Kelly (PA)
 Brat Fleischmann King (IA)
 Bridenstine Flores King (NY)
 Brooks (AL) Fortenberry Kinzinger
 Brooks (IN) Foxx Knight
 Buchanan Franks (AZ) Kustoff (TN)
 Buck Frelinghuysen Labrador
 Bucshon Gaetz LaHood
 Budd Gallagher LaMalfa
 Burgess Garrett Lamborn
 Byrne Gianforte Lance
 Calvert Gibbs Latta
 Carter (GA) Goodlatte Lewis (MN)
 Carter (TX) Gosar LoBiondo
 Chabot Gowdy Long
 Cheney Granger Loudermilk
 Coffman Graves (GA) Love
 Cole Graves (LA) Lucas
 Collins (GA) Graves (MO) Luetkemeyer
 Collins (NY) Griffith MacArthur
 Comer Grothman Marchant
 Comstock Handel Marino
 Conaway Harper Marshall
 Cook Harris Massie
 Costello (PA) Hartzler Mast
 Cramer Herrera Beutler McCarthy
 Crawford Hice, Jody B. McCaul

McClintock Rice (SC) Stewart
 McHenry Roby Stivers
 McKinley Roe (TN) Taylor
 McMorris Rogers (AL) Tenney
 Rodgers Rogers (KY) Thompson (PA)
 McSally Rohrabacher Thornberry
 Meadows Rokita Tiberi
 Meehan Rooney, Francis Tipton
 Messer Rooney, Thomas Trott
 Mitchell J. Turner
 Moolenaar Ros-Lehtinen Upton
 Mooney (WV) Roskam Valadao
 Mullin Ross Wagner
 Murphy (PA) Rothfus Walberg
 Newhouse Rouzer Walden
 Noem Royce (CA) Walker
 Norman Russell Walorski
 Nunes Rutherford Walters, Mimi
 Olson Sanford Weber (TX)
 Palazzo Schwei kert Webster (FL)
 Palmer Scott, Austin Wenstrup
 Paulsen Sensenbrenner Westerman
 Pearce Sessions Williams
 Perry Shimkus Wilson (SC)
 Pittenger Shuster Wittman
 Poe (TX) Simpson Womack
 Poliquin Smith (MO) Woodall
 Smith (NE) Smith (NE) Yoder
 Smith (NJ) Smith (NJ) Yoho
 Smith (TX) Smith (TX) Young (AK)
 Renacci Smucker Young (IA)
 Stefanik Stefanik Zeldin

NOES—187

Adams Gallego Nolan
 Aguilar Garamendi Norcross
 Barragan Gohmert O'Halleran
 Bass Gomez O'Rourke
 Beatty Gonzalez (TX) Pallone
 Bera Gottheimer Panetta
 Beyer Green, Al Pascrell
 Bishop (GA) Green, Gene Payne
 Blumenauer Grijalva Perlmutter
 Blunt Rochester Gutiérrez Peters
 Bonamici Hanabusa Peterson
 Boyle, Brendan Hastings Pingree
 F. Heck Pocan
 Brady (PA) Higgins (NY) Polis
 Brown (MD) Himes Price (NC)
 Brownley (CA) Hoyer Quigley
 Bustos Huffman Raskin
 Butterfield Jackson Lee Rice (NY)
 Capuano Jayapal Richmond
 Carbajal Jeffries Rosen
 Cárdenas Johnson (GA) Roybal-Allard
 Carson (IN) Johnson, E. B. Ruiz
 Cartwright Kaptur Ruppertsberger
 Castor (FL) Keating Rush
 Castro (TX) Kelly (IL) Ryan (OH)
 Chu, Judy Kennedy Sánchez
 Cicilline Kihuen Sarbanes
 Clark (MA) Kildee Schakowsky
 Clarke (NY) Kilmer Schiff
 Clay Kind Schneider
 Cleaver Krishnamoorthi Schrader
 Clyburn Kuster (NH) Scott (VA)
 Cohen Langevin Scott, David
 Connolly Larsen (WA) Serrano
 Conyers Larson (CT) Sewell (AL)
 Cooper Lawrence Sherman
 Correa Lawson (FL) Sinema
 Courtney Sires Sires
 Crist Levin Slaughter
 Cuellar Lewis (GA) Smith (WA)
 Davis (CA) Davis (CA) Soto
 Davis, Danny Loeb sack Speier
 DeFazio Lofgren Suozzi
 DeGette Lowenthal Swalwell (CA)
 Delaney Lowey Takano
 DeLauro Lujan Grisham, Thompson (CA)
 DelBene M. Thompson (MS)
 Demings Luján, Ben Ray Titus
 DeSaulnier Lynch Tonko
 Dingell Maloney, Carolyn B. Torres
 Doggett Maloney, Sean Tsongas
 Doyle, Michael F. Maloney, Sean Vargas
 Ellison Matsui Veasey
 Engel McCollum Vela
 Eshoo McEachin Velázquez
 Espallat McGovern Visclosky
 Esty (CT) Mc Nerney Walz
 Evans Meeks Wasserman
 Foster Meng Schultz
 Waters, Maxine
 Watson Coleman
 Wilson (FL)
 Yarmuth

NOT VOTING—14

Barletta Guthrie Napolitano
 Barr Hensarling Pelosi
 Costa Johnson, Sam Scalise
 Crowley Khanna Shea-Porter
 Cummings Lieu, Ted

□ 1452

Mr. LOEBSACK changed his vote from “aye” to “no.”

So the resolution was agreed to.

The result of the vote was announced as above recorded.

A motion to reconsider was laid on the table.

ANNOUNCEMENT BY COMMITTEE ON RULES REGARDING AMENDMENT PROCESS FOR H.R. 806, OZONE STANDARDS IMPLEMENTATION ACT OF 2017, AND H.R. 2997, 21ST CENTURY AVIATION INNOVATION, REFORM, AND REAUTHORIZATION ACT

Mr. SESSIONS. Mr. Speaker, this morning the Rules Committee issued announcements outlining the amendment processes for two measures that will likely be before the Rules Committee next week.

An amendment deadline has been set for Monday, July 17, at 10 a.m., for H.R. 806, the Ozone Standards Implementation Act of 2017; and Monday, July 17, at noon, for H.R. 2997, the 21st Century AIRR Act.

The text of these measures is presently available on the Rules Committee website.

Feel free to contact me or my staff if we may provide any additional information.

MEDICAL CONTROLLED SUBSTANCES TRANSPORTATION ACT OF 2017

The SPEAKER pro tempore. Without objection, 5-minute will continue.

There was no objection.

The SPEAKER pro tempore. The unfinished business is the vote on the motion to suspend the rules and pass the bill (H.R. 1492) to amend the Controlled Substances Act to direct the Attorney General to register practitioners to transport controlled substances to States in which the practitioner is not registered under the Act for the purpose of administering the substances (under applicable State law) at locations other than principal places of business or professional practice, on which the yeas and nays were ordered.

The Clerk read the title of the bill.

The SPEAKER pro tempore. The question is on the motion offered by the gentleman from Texas (Mr. BURGESS) that the House suspend the rules and pass the bill.

This is a 5-minute vote.

The vote was taken by electronic device, and there were—yeas 416, nays 2, not voting 15, as follows:

[Roll No. 349]

YEAS—416

Abraham
 Adams
 Aderholt
 Aguilar
 Allen
 Amash
 Amodei
 Arrington
 Babin
 Bacon
 Banks (IN)
 Barletta
 Barragán
 Barton
 Bass
 Beatty
 Bera
 Bergman
 Beyer
 Ellison
 Biggs
 Bilirakis
 Bishop (GA)
 Bishop (MI)
 Bishop (UT)
 Black
 Blackburn
 Blum
 Blumenauer
 Blunt Rochester
 Bonamici
 Bost
 Boyle, Brendan F.
 Brady (PA)
 Brady (TX)
 Brat
 Bridenstine
 Brooks (AL)
 Brooks (IN)
 Brown (MD)
 Brownley (CA)
 Buchanan
 Buck
 Bucshon
 Budd
 Burgess
 Bustos
 Butterfield
 Byrne
 Calvert
 Capuano
 Carbajal
 Cárdenas
 Carson (IN)
 Carter (GA)
 Carter (TX)
 Cartwright
 Castor (FL)
 Castro (TX)
 Chabot
 Cheney
 Chu, Judy
 Cicilline
 Clark (MA)
 Clarke (NY)
 Clay
 Cleaver
 Clyburn
 Coffman
 Cohen
 Cole
 Collins (GA)
 Collins (NY)
 Comer
 Comstock
 Conaway
 Connolly
 Conyers
 Cook
 Cooper
 Correa
 Costello (PA)
 Courtney
 Cramer
 Crawford
 Crist
 Cuellar
 Culberson
 Curbelo (FL)
 Davis (CA)
 Davis, Danny
 Davis, Rodney
 DeFazio
 DeGette
 Delaney
 DeLauro
 DeBene
 Demings
 Denham
 Demchak
 Dent
 DeSantis
 DeSaulnier
 DesJarlais
 Deutch
 Diaz-Balart
 Dingell
 Doggett
 Donovan
 Doyle, Michael F.
 Duffy
 Duncan (SC)
 Duncan (TN)
 Dunn
 Ellison
 Emmer
 Engel
 Eshoo
 Espallat
 Estes (KS)
 Esty (CT)
 Evans
 Farenthold
 Faso
 Ferguson
 Fitzpatrick
 Fleischmann
 Flores
 Fortenberry
 Foster
 Foy
 Frankel (FL)
 Franks (AZ)
 Frelinghuysen
 Fudge
 Gabbard
 Gaetz
 Gallagher
 Gallego
 Garamendi
 Garrett
 Gianforte
 Gibbs
 Gomez
 Gonzalez (TX)
 Goodlatte
 Gosar
 Gottheimer
 Gowdy
 Granger
 Graves (GA)
 Graves (LA)
 Graves (MO)
 Green, Al
 Green, Gene
 Griffith
 Grijalva
 Grothman
 Hanabusa
 Handel
 Harper
 Harris
 Hartzer
 Hastings
 Heck
 Hensarling
 Herrera Beutler
 Hice, Jody B.
 Higgins (LA)
 Higgins (NY)
 Hill
 Himes
 Holding
 Hollingsworth
 Hoyer
 Hudson
 Huffman
 Huizenga
 Hultgren
 Hunter
 Hurd
 Issa
 Jackson Lee
 Jayapal
 Jeffries
 Jenkins (KS)
 Jenkins (WV)
 Johnson (GA)
 Johnson (LA)
 Johnson (OH)
 Johnson, E. B.
 Jones
 Jordan
 Joyce (OH)
 Kaptur
 Katko
 Keating
 Kelly (IL)
 Kelly (MS)
 Kelly (PA)
 Kennedy
 Kihuen
 Kildee
 Kilmer
 Kind
 King (IA)
 King (NY)
 Kinzinger
 Knight
 Krishnamoorthi
 Kuster (NH)
 Kustoff (TN)
 Labrador
 LaMalfa
 Lamborn
 Lance
 Langevin
 Larsen (WA)
 Larson (CT)
 Latta
 Lawrence
 Lawson (FL)
 Lee
 Levin
 Lewis (GA)
 Lewis (MN)
 Lipinski
 LoBiondo
 Loeb sack
 Lofgren
 Long
 Loudermilk
 Love
 Lowenthal
 Lowey
 Lucas
 Luetkemeyer
 Lujan Grisham, M.
 Luján, Ben Ray
 Lynch
 MacArthur
 Maloney, Carolyn B.
 Maloney, Sean
 Marchant
 Marino
 Marshall
 Mast
 Matsui
 McCarthy
 McCaul
 McClintock
 McCollum
 McEachin
 McGovern
 McHenry
 McKinley
 McMorris
 Rodgers
 McNERNEY
 McSally
 Meadows
 Meehan
 Meeks
 Meng
 Messer
 Mitchell
 Moolenaar
 Mooney (WV)
 Moore
 Moulton
 Mullin
 Murphy (FL)
 Murphy (PA)
 Nadler
 Neal
 Newhouse
 Noem
 Nolan
 Norcross
 Norman
 Nunes
 O'Halleran
 O'Rourke
 Olson
 Palazzo
 Pallone

Palmer
 Panetta
 Pascrell
 Paulsen
 Payne
 Pearce
 Pelosi
 Perlmutter
 Perry
 Peters
 Peterson
 Pingree
 Pittenger
 Pocan
 Poe (TX)
 Poliquin
 Polis
 Posey
 Price (NC)
 Quigley
 Raskin
 Ratcliffe
 Reichert
 Renacci
 Rice (NY)
 Rice (SC)
 Richmond
 Roby
 Roe (TN)
 Rogers (AL)
 Rogers (KY)
 Rohrabacher
 Rokita
 Rooney, Francis
 Rooney, Thomas J.
 Ros-Lehtinen
 Rosen
 Roskam
 Ross
 Rothfus
 Rouzer
 Long
 Roybal-Allard
 Royce (CA)
 Ruiz
 Ruppertsberger
 Rush
 Russell
 Rutherford
 Ryan (OH)
 Sánchez
 Sanford
 Sarbanes
 Schakowsky
 Schiff
 Schneider
 Schrader
 Schweikert
 Scott (VA)
 Scott, Austin
 Scott, David
 Sensenbrenner
 Serrano
 Sessions
 Sewell (AL)
 Sherman
 Shimkus
 Shuster
 Simpson
 Sinema
 Sires
 Slaughter
 Smith (MO)
 Smith (NE)
 Smith (NJ)
 Smith (TX)
 Smith (WA)
 Smucker
 Soto
 Speier
 Stefanik
 Stewart
 Stivers
 Suozzi
 Swalwell (CA)
 Takano
 Taylor
 Tenney
 Thompson (CA)
 Thompson (MS)
 Thompson (PA)
 Thornberry
 Tiberi
 Tipton
 Titus
 Tonko
 Torres
 Trott
 Tsongas
 Turner
 Upton
 Valadao
 Vargas
 Veasey
 Vela
 Velázquez
 Vislosky
 Wagner
 Walberg
 Walden
 Walker
 Walorski
 Walters, Mimi
 Walz
 Wasserman
 Schultz
 Waters, Maxine
 Watson Coleman
 Weber (TX)
 Webster (FL)
 Welch
 Wenstrup
 Westerman
 Williams
 Wilson (FL)
 Wilson (SC)
 Wittman
 Womack
 Woodall
 Yarmuth
 Yoder
 Yoho
 Young (AK)
 Young (IA)
 Zeldin

NAYS—2

Gohmert
 Massie
 Guthrie
 Gutiérrez
 Johnson, Sam
 Khanna
 LaHood
 Lieu, Ted
 Napolitano
 Reed
 Scalise
 Shea-Porter

NOT VOTING—15

□ 1506

So (two-thirds being in the affirmative), the rules were suspended and the bill was passed.

The result of the vote was announced as above recorded.

A motion to reconsider was laid on the table.

PERSONAL EXPLANATION

Mrs. NAPOLITANO. Mr. Speaker, I was absent during rollcall votes No. 347, No. 348, and No. 349 due to my spouse's health situation in California. Had I been present, I would have voted “nay” on the Motion on Ordering the Previous Question on the Rule providing for consideration of both H.R. 23 and H.R. 2810. I would have also voted “nay” on H. Res. 431—Rule providing for consideration of both H.R. 23—Gaining Responsibility on Water Act of 2017 and H.R. 2810—National Defense Authorization Act for Fiscal Year 2018. I would have also voted “yea” on H.R. 1492—Medical Controlled Substances Transportation Act of 2017.

PERSONAL EXPLANATION

Mr. CROWLEY. Mr. Speaker, on July 12, 2017, due to a family commitment I was absent for recorded votes No. 347, No. 348, and No. 349. Had I been present, on rollcall No. 347, I would have voted “no”; on rollcall No. 348, I would have voted “no”; and on rollcall No. 349, I would have voted “yes.”